Monday, May 02, 2022 11:05:32 AM
During fiscal year 2021, Mr. Dowling's total compensation was $1,206,814, which included his salary for fiscal year 2021
of $320,523, a repayment of $80,000 deferred compensation from 2020, the issuance of 1,500,000 stock options, and a $18,000
33
auto allowance. Mr. Dowling's target for his performance bonus was 50% of his annual salary; however, as noted above, due to the
Company's financial performance for fiscal year 2021, no bonuses were paid for 2021. During fiscal year 2020, Mr. Dowling's total
compensation was $863,079, which included his salary of $362,099, the issuance of 1,500,000 stock options, $51,399 of incremental
expense related to the repricing of certain of his stock options in June 2020, and a $16,500 auto allowance. Mr. Dowling's target for
his performance bonus was 50% of his annual salary; however, as noted above, due to the Company's financial performance for
fiscal year 2020, no bonuses were paid for 2020.
During fiscal year 2021, Mr. Grasser's total compensation was $645,690, which included his salary for fiscal year 2021 of
$211,545, a repayment of $40,000 deferred compensation from 2020, and the issuance of 750,000 stock options. Mr. Grasser's target
for his performance bonus was 20% of his annual salary; however, as noted above, due to the Company's financial performance for
fiscal year 2021, no bonuses were paid for 2021. During fiscal year 2020, Mr. Grasser's total compensation was $482,650, which
included his salary of $214,711, the issuance of 750,000 stock options, and $51,399 of incremental expense related to the repricing
of certain of his stock options in June 2020.
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:36:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:21:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 01:32:15 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM